Abivax Stock: Shares Fall Below 50-Day Moving Average, Less Than a Month Before Annual Results
Abivax shares are down 1.89% this Thursday morning, trading at €104.00, continuing a downward trend that began a week ago. The stock of the French biotech company is now slightly below its 50-day moving average, in a context where the publication of the 2025 annual results is expected on March 23.
Recent Performance and Technical Levels
Abivax stock has declined by 5.8% over the past seven days, bringing the three-month contraction to 4.06%. At €104.00, the price has fallen below its 50-session moving average, established at €104.73, a technical level monitored by market operators. This downward crossing occurs as the RSI, an indicator measuring the momentum of the stock in recent sessions, stands at 68, indicating a high but retreating level from overbought conditions. The proximity of the resistance threshold at €112.40 had hindered the stock's progress in recent weeks, while the support identified at €93.70 represents the next technical level if the downward movement continues. Over one year, however, the performance remains exceptional, with a rise of 1,353%, reflecting the massive revaluation of the company following its clinical advancements. The monthly volatility, measured at 11.17, indicates significant fluctuations, typical for a stock in the biotechnology sector.
Upcoming Catalyst: 2025 Annual Accounts
The next identified catalyst for Abivax lies in the presentation of the 2025 annual accounts, scheduled for March 23. This deadline is particularly significant for a company that, in an advanced phase of developing its therapeutic portfolio, remains structurally unprofitable and dependent on its available cash. Observers will be keen to monitor the cash burn rate as well as the progress of clinical programs, notably obefazimod, the group's flagship drug candidate for chronic inflammatory bowel diseases. The financial calendar then schedules the results for the first quarter of 2026 on June 1, followed by the half-year results on September 14. These appointments will mark the coming months and progressively provide visibility on the operational and financial trajectory of the Parisian biotech. In the immediate term, the price decline near intermediate technical levels is part of a consolidation phase after the spectacular rise recorded over the past year.
